What is Spiracur?
Headquartered in Sunnyvale, California, Spiracur Inc. is a specialized medical device manufacturer born from the Stanford University Biodesign Innovation Program. The company focuses on the development of innovative wound healing technologies, most notably the SNaP Therapy System and the ciSNaP Closed Incision System. These products are engineered to provide controlled tension relief and effective wound management without the need for batteries or electricity, offering a significant improvement over traditional, bulky negative pressure systems. With FDA 510(k) clearance and CE Mark approval, Spiracur maintains a strong regulatory standing, enabling broad market access for its proprietary, mechanically powered clinical solutions.
How much funding has Spiracur raised?
Spiracur has raised a total of $75.5M across 4 funding rounds:
Series A
$4.2M
Series B
$20.3M
Unspecified
$35M
Debt
$16M
Series A (2007): $4.2M, investors not publicly disclosed
Series B (2009): $20.3M led by Kleiner Perkins Caufield & Byers, New Leaf Venture Partners, and De Novo Ventures
Unspecified (2011): $35M supported by Kleiner Perkins Caufield & Byers, New Leaf Venture Partners, Pinnacle Ventures, De Novo Ventures, and Maverick Capital
Debt (2014): $16M featuring GE Capital
Key Investors in Spiracur
Kleiner Perkins Caufield & Byers
Kleiner Perkins is a Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology and life-science companies, backing founders across consumer, enterprise, healthcare, and climate/hard tech with capital and operational support from seed through IPO or acquisition.
New Leaf Venture Partners
New Venture Partners LLC is a global venture capital firm dedicated to corporate technology spinouts, providing a bridge between technology corporations and traditional venture capital through a systematic process for commercializing innovations.
GE Capital
General Electric Company operates as a global infrastructure and technology company, specializing in multiple sectors including power generation, renewable energy, aviation, and healthcare, providing industrial automation and digital services.
What's next for Spiracur?
Looking ahead, Spiracur is well-positioned to capitalize on the increasing demand for high-risk surgical incision management and chronic wound care efficiency. The recent infusion of capital provides the necessary runway to expand its commercial footprint and potentially explore new clinical applications for its tension-relief technology. As the company continues to refine its operational strategy, the focus will likely remain on deepening market penetration and maintaining its competitive edge through continued clinical validation and strategic partnerships. By leveraging its established intellectual property, Spiracur is poised to sustain its growth trajectory within the global healthcare landscape, ensuring that its non-powered, patient-friendly devices remain at the forefront of surgical recovery standards.
See full Spiracur company page
